Current Report Filing (8-k)
September 13 2022 - 04:32PM
Edgar (US Regulatory)
NASDAQ false 0001205922 0001205922
2022-09-12 2022-09-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 12, 2022
Vaccinex, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
Delaware |
|
001-38624 |
|
16-1603202 |
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
| 1895 Mount Hope Avenue,
Rochester, New York |
|
14620 |
| (Address of principal
executive offices) |
|
(Zip Code) |
(585) 271-2700
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Stock, par value $0.0001 per
share |
|
VCNX |
|
Nasdaq Capital
Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this
chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
| Item 7.01 |
Regulation FD Disclosure.
|
On September 12, 2022, Vaccinex, Inc. (the “Company”)
presented at the ESMO Congress 2022. A copy of the presentation
presented by the Company is furnished herewith as Exhibit 99.1 and
is available on the Company’s website located at www.vaccinex.com under the
heading “Presentations.”
The information furnished pursuant to this Item 7.01, including
Exhibit 99.1 shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”) or otherwise subject to the liabilities under
such section and shall not be deemed to be incorporated by
reference into any filing of the Company under the Securities Act
of 1944, as amended, or the Exchange Act.
| Item 9.01 |
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
VACCINEX, INC. |
| Date: September 13,
2022 |
|
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Scott E. Royer
|
|
|
|
|
|
|
Scott E. Royer |
|
|
|
|
|
|
Chief Financial Officer |
Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From Apr 2023 to May 2023
Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From May 2022 to May 2023
